Loteprednol etabonate gel 0.5 for postoperative pain and inflammation after cataract surgery: results of a multicenter trial

摘要

PurposeLoteprednol etabonate (LE) is approved by the US FDA in a suspension and ointment form (0.5%) for the treatment of postoperative ocular inflammation. This study examined the gel formulation of LE, an improved, nonsettling formulation with a lower preservative level and a more physiologic pH.